Is NewcelX Ltd. (NCEL) a Buy, Sell, or Hold?
NASDAQ : NCEL
NewcelX Ltd.
$3.49 USD
$0.13 (3.83%)
- Volume
- 10.1K
- Average Volume
- 38.63K
- Market Capitalization
- $1.57M
- P/E Ratio
- -0.38
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $28.03
- Year Low
- $1.83
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.76
Company Overview
NASDAQ
Ronen Twito
Biotechnology
Healthcare
NCEL
11
CH
USD
Liquidity Metrics
0.05
0.76
0.76
0.52
0.00
Sales & Valuation
-$
0.00
1.62
-0.76
-0.62
Profitability
-$2.16
-$8.3M
0.00%
0.00%
41.94%
18.57%
P/E Metrics
-0.38
-0.02
-0.02
Analyst Price Target & Rating
4/5
2 Analysts
%
Financial Health Scores
-12.22
3/9
-$1.01M
$11.44M
$4.2M
-$6.78M
Key Metrics (TTM)
-$333.37K
0.00
0.10
0.76
41.94%
-75.27%
18.77%
-137.23%
$5.53
-351951 days
Company Executives
| Name | Title |
|---|---|
| Ariel Revel | Director of Medical Affairs |
| Omri Hagai | Chief Financial Officer |
| Michel Revel | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director |
| Eric Konofal | Head of Doxa Program |
| Yossi Ben-Yossef | Honorary President & Strategic Consultant |
| Alexander Zwyer | Chief Business Officer & Executive Director |
| Ronen Twito | Chief Executive Officer & Executive Chairman |
Poll Results
No votes yet today — be the first to share your view!
About NewcelX Ltd. (NASDAQ:NCEL) Stock
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases. ...
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
2026-07-31 09:00:00
Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting Private Financing Reflects Strong Investor Confidence and Supports Advancement of Lead Type 1 Diabetes Program Following Successful FDA Pre-IND Meeting
2026-07-08 09:15:00
The appointment follows New c elX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101 , providing a clear regulatory pathway toward clinical trials
2026-07-01 09:30:00
FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX's planned development strategy for NCEL-101 in combination with Tegoprubart
2026-06-15 08:30:00
Study published in Stem Cell Reports demonstrat e s that AstroRx ® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
2026-05-27 07:55:00
Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug (“Pre-IND”) briefing package to the U.S. Food and Drug Administration (“FDA”) to support the proposed First-In-Human (“FIH”) clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (“Eledon”; Nasdaq: ELDN).
Frequently Asked Questions
-
What is the current NewcelX Ltd. (NCEL) stock price?
-
NewcelX Ltd.(NASDAQ:NCEL) stock price is $3.49 in the last trading session. During the trading session, NCEL stock reached the peak price of $28.03 while $1.83 was the lowest point it dropped to. The percentage change in NCEL stock occurred in the recent session was 3.83% while the dollar amount for the price change in NCEL stock was $0.13.
-
NCEL's industry and sector of operation?
-
The NASDAQ listed NCEL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NCEL?
-
Ariel Revel | Director of Medical Affairs
Omri Hagai | Chief Financial Officer
Michel Revel | Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director
Eric Konofal | Head of Doxa Program
Yossi Ben-Yossef | Honorary President & Strategic Consultant -
How many employees does NCEL have?
-
Number of NCEL employees currently stands at 11. NCEL operates from The Circle 6, Kloten, ZH 8058, CH.
-
Link for NCEL official website?
-
Official Website of NCEL is: https://newcelx.net
-
How do I contact NCEL?
-
NCEL could be contacted at phone #972 73 797 1600 and can also be accessed through its website. NCEL operates from The Circle 6, Kloten, ZH 8058, CH.
-
How many shares of NCEL are traded daily?
-
The average number of NCEL shares traded daily for last 3 months was 38.63K.
-
What is the market cap of NCEL currently?
-
The market value of NCEL currently stands at $1.57M with its latest stock price at $3.49